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Background: Chronic cerebrospinal venous insufficiency (CCSVI) is a vascular condition characterized by anomalies
of the primary veins outside the skull that has been reported to be associated with MS. In the blinded Combined
Transcranial (TCD) and Extracranial Venous Doppler Evaluation (CTEVD) study, we found that prevalence of CCSVI
was significantly higher in multiple sclerosis (MS) vs. healthy controls (HC) (56.1% vs. 22.7%, p< 0.001).
The objective was to evaluate the clinical correlates of venous anomalies indicative of CCSVI in patients with MS.
Methods: The original study enrolled 499 subjects; 163 HC, 289 MS, 21 CIS and 26 subjects with other neurological
disorders who underwent a clinical examination and a combined Doppler and TCD scan of the head and neck. This
analysis was restricted to adult subjects with MS (RR-MS: n= 181, SP-MS: n= 80 and PP-MS: n= 12). Disability status
was evaluated by using the Kurtzke Expanded Disability Status Scale (EDSS) and MS severity scale (MSSS).
Results: Disability was not associated with the presence (≥2 venous hemodynamic criteria) or the severity of CCSVI,
as measured with venous hemodynamic insufficiency severity score (VHISS). However, the severity of CCSVI was
associated with the increased brainstem functional EDSS sub-score (p= 0.002). In logistic regression analysis,
progressive MS (SP-MS or PP-MS) vs. non-progressive status (including RR-MS) was associated with CCSVI diagnosis
(p= 0.004, OR = 2.34, CI = 1.3–4.2).
Conclusions: The presence and severity of CCVSI in multiple sclerosis correlate with disease status but has no or
very limited association with clinical disability.
Search terms: Multiple sclerosis, Disease progression, Disability, Echo-color Doppler, Venous anomalies, CCSVIBackground
Multiple sclerosis (MS) is considered a chronic disease
of the brain and spinal cord characterized by
inflammatory-demyelinating and neurodegenerative fea-
tures that coexist from early stages [1,2]. The heteroge-
neous clinical presentation and dissimilar long-term
outcomes support a complex MS pathobiology. The re-
cent findings of Zamboni et al. [3-5], who identified a
strong association between MS and a condition defined
as chronic cerebrospinal venous insufficiency (CCSVI)
provide a different viewpoint on the possible cause
and progression of MS. However, the relationship of* Correspondence: BWeinstock-Guttman@Kaleidahealth.org
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distribution, and reproduction in any mediumCCSVI to MS pathogenesis is unproven, and sensitivity/
specificity findings have ranged from perfect [3] to in-
termediate [6-13] to null association [14-19]. These
contradictory research findings have fueled a polarizing
controversy between practitioners and MS patients [20-
23]. Therefore a critical objective independent validation
of the existence of CCSVI in MS patients and certainly
establishing whether CCSVI is a cause, consequence or
mere association with MS becomes imperative.
CCSVI has been described as a vascular condition
characterized by anomalies of the main extra-cranial
cerebrospinal (CS) venous routes that interfere with nor-
mal CS venous outflow. These anomalies have been
reported to affect the internal jugular veins (IJV), the
vertebral veins (VV) and the azygous vein (AZY), and
can be detected using a noninvasive combined venousMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Doppler and confirmed by selective venography [3-5]. It
has been hypothesized that CS venous anomalies may
cause alterations to blood flow that eventually result in
iron deposition, decreased brain parenchyma metabol-
ism, degeneration of neurons and characteristic brain in-
jury patterns found in MS [24,25].
In an independent study [9] using identical EC/TCD
method as described by Zamboni, our group showed re-
cently a significant association between MS and pres-
ence of CCSVI compared to a healthy control group
(p < 0.001). The goal of the present additional analysis
within the initial large heterogeneous MS cohort was to
determine the associations of venous hemodynamic
findings according to the Zamboni CCSVI criteria with
clinical disease severity and classification of disease sta-




The study was approved by the University at Buffalo
Human Subjects Institutional Review Board (HSIRB
#NEU2490109A). Written informed consent was
obtained from all participants.
Study design
This cross-sectional study aims to evaluate the clinical
correlates of a large cohort of MS patients in relation to
the CCSVI criteria [3]. The study represents a post-hoc
analysis of the original Combined Transcranial and
Extracranial Venous ECD Evaluation (CTEVD) study
which was designed to assess the prevalence of CCSVI
in a large cohort of patients with MS, healthy controls
and controls with other neurological diseases (OND)
using specific ECD criteria [3,9]. This CTEVD phase 1
study enrolled 289 MS and 21 clinically isolated syn-
drome (CIS) patients [9]. The participants received a
clinical examination (BWG and DH, that were blinded
to the Doppler findings) and an ECD scan of the head
and neck (performed by a technician blinded to the sub-
jects’ diagnosis) [9]. The clinical evaluation included
neurological assessment using the Kurtzke Expended
Disability Status Score (EDSS) based on its separate
functional scores and gait endurance [26]. The EDSS
was further converted to the MS Severity Scores (MSSS)
scale that was designed as a comparative MS population
disability assessment tool, to allow comparisons of rela-
tive disease severity at all EDSS levels for a given disease
duration, using a single clinical assessment at a single
point in time [27]. The ECD outcome measure of inter-
est included the presence of CCSVI, as previously
defined [3]. Additional ECD outcomes included the indi-
vidual Doppler Criteria 1–5 and CCSVI severity, asmeasured by venous hemodynamic insufficiency severity
score (VHISS) [3].Echo-color doppler data analysis
Combined transcranial and extracranial ECD allows for
non-invasive assessment of venous hemodynamic (VH)
parameters indicative of CCSVI [3,4]. Cerebral venous
return was examined by using the echo-color Doppler
(ECD Esaote-Biosound My Lab 25) equipped with 2.5
and 7.5–10 Mhz transducers (Genoa, Italy), with the
subject positioned on a tilt bed at 90° and 0° [3,4].
The specific details of subject length of exam, contra-
indications and limitations, subject assessment, examin-
ation guidelines, annotation documentation, specific
Doppler parameters, criteria definitions, description of
probes, positioning of the subject, hydration status, tech-
niques used, fulfilment of VH criteria and pathology
definitions are provided elsewhere [9].
Each subject was assigned a total criteria VH score
that was calculated by counting the number of criteria
that the subject fulfilled. A subject was considered
CCSVI-positive if ≥ 2 VH criteria were fulfilled. Subjects
who were not assessed for some VH criterion, due to
technical difficulty, were assumed not to have fulfilled
that criterion.
The five VH criteria evaluated are: Criterion 1) reflux
in the IJVs and/or in the VVs assessed in both sitting
and supine postures, Criterion 2) reflux in the deep cere-
bral veins (DCVs), Criterion 3) B-mode detection of
stenoses in the IJVs in the form of annuli, webs, septa,
or malformed valves, Criterion 4) absence of ECD signal
in the IJV and/or in the VVs, even after forced deep
breaths, and Criterion 5) presence of a negative differ-
ence in the cross sectional area (CSA) of the IJV. The se-
verity of CCSVI was measured by VHISS, as previously
reported [3]. VHISS is based on the sum of pathologic
parameters measured for each of the 5 criteria examined.
VHISS is ranging from 0 to 16.Data analysis
SPSS (SPSS Inc., Chicago, IL, version 15.0) statistical
program was used for all statistical analyses. The sub-
jects with relapsing-remitting (RR) MS were categorized
as non-progressive MS whereas subjects with relapsing
and relapse-free forms of secondary progressive (SP) and
primary-progressive (PP) MS were categorized as pro-
gressive MS.
One-way ANOVA followed by post-hoc independent
sample t-tests were used to test for differences in means
of continuous demographic variables such as age, age of
onset, and disease duration. The χ2 test was used for
analysis of count variables for categorical data and the
Fisher exact test was used where appropriate.
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gressive MS status as the dependent variable, age as a
covariate and gender as a factor was also used to assess
the role of CCSVI. Analyses were conducted with main
effects models containing CCSVI.
The EDSS values were dichotomized into EDSS≥4 and
EDSS<4.0. The EDSS categories were analyzed as the
dependent variable in logistic regression with sex and age
and either presence of CCSVI or VHISS as predictors. The
MSSS was analyzed as the dependent variable with linear
regression with sex and age and either presence of CCSVI
or VHISS as predictors. VHISS and number of venous
hemodynamic criteria fulfilled were analyzed as dependent
variable in Poisson regression with sex as a factor and age
as a covariate. The EDSS sub-scores were analyzed with or-
dinal regression with age as a covariate, sex as a factor and
either presence of CCSVI or VHISS as predictors.
In order to avoid too many spurious findings due to
multiple comparisons, we do not report anything as sta-
tistically significant unless the nominal p-value was
≤ 0.01 by using two-tailed tests. A trend was assumed
with Type 1 error level of 0.1.
Results
Demographic and clinical characteristics
The present analysis was restricted to adult subjects with
RR-MS (n= 181), SP-MS (n= 80) and PP-MS (n= 12)
disease courses. Healthy controls (n= 163), subjects with
CIS (n= 21), pediatric-onset MS (n= 10), NMO (n= 6)
and OND (n= 23) were excluded from the original co-
hort including 499 subjects [9].
Relapsing (n= 19) and non-relapsing SP-MS (n= 61)
were grouped in to a single SP-MS category and simi-
larly relapsing (n= 1) and non-relapsing primary (n= 11)
progressive MS were grouped together in the PP-MS
group. Table 1 shows demographic and clinical charac-
teristics of the enrolled MS groups.
No age, sex or disease duration differences were found
in the RR-MS and SP-MS in subjects either with or
without the presence of CCSVI (all p > 0.05 in t-tests forTable 1 Demographic and clinical characteristics of the enroll




Females: Males (% Female) 208: 65 (76.2%) 138: 43 (76
Age, years 47.7 ± 10.7 44.7 ± 10.0
Disease duration*, years 15.2 ± 10.5 12.1 ± 8.3
Median EDSS* (IQR) 3.0 (4.0) 2.0 (1.5)
MSSS 4.05 ± 2.51 3.08 ± 2.12
Treatment duration, years 3.8 ± 3.7 3.4 ± 3.5
* From symptoms.
Female to male ratio: χ2 test; Age, disease duration, MSSS, treatment duration: one-
MS multiple sclerosis; PP primary progressive, RR relapsing-remitting; SP econdary page and disease duration and χ2 test for sex differences,
data not shown). The PP-MS patients with CCSVI were
older (59.3 ± 6.3 years) than those without CCSVI
(49.8 ± 6.8 years) but the sex distribution and disease
duration were similar.
Of the 273 MS, 238/268 (88.8%) were on disease-
modifying therapies; data were unavailable for 5 patients
(Table 1). No differences in age at disease onset, disease
diagnosis or number of relapses during the preceding
year were seen between the CCSVI positive or negative
groups (data not shown).
Disease state and CCSVI
Table 2 shows the prevalence of CCSVI classifications
for MS patients by subtype of MS. The highest preva-
lence was seen in SP-MS, followed by PP-MS and RR-
MS. In logistic regression correcting for age and sex,
progressive MS (SP-MS or PP-MS) vs. non-progressive
status (RR-MS) was associated with CCSVI diagnosis
(p= 0.004, OR= 2.34, CI = 1.3–4.2).
As expected, VHISS was significantly higher for MS
patients diagnosed with CCSVI (Mean±SD: 4.20±1.4) than
for subjects without CCSVI (Mean±SD: 1.28±1.0; p< .001
from a Mann–Whitney test). Table 2 gives the distribution
of VHISS for the MS disease groups. The MS disease groups
(p<0.001, Kruskall-Wallis) significantly differed in VHISS.
Disability status and CCSVI diagnosis
The three MS subtypes significantly differed on total EDSS
score (p<0.001, Kruskall-Wallis test) and all EDSS sub-
scores (p<0.001 for each, Kruskall-Wallis test). The prob-
ability of EDSS≥4 was not associated with the presence of
CCSVI (p=0.42) in logistic regression correcting for age
and sex. In ordinal regression correcting for sex and age, the
presence of CCSVI diagnosis exhibited a trend with the
EDSS brain stem sub-score (p=0.074).
Table 1 gives the distribution of MSSS for the MS
disease groups. No evidence for differences in mean
MSSS ± SD for subjects diagnosed with CCSVI






.2%) 63: 17 (78.8%) 7: 5 (58.3%) 0.34
53.3 ± 9.7 54.6 ± 8.0 < 0.001
21.9 ± 12.0 15.8 ± 9.4 < 0.001
6.0 (1.5) 5.75 (3.13) < 0.001
5.87 ± 2.11 6.06 ± 2.71 < 0.001
4.8 ± 4.1 3.4 ± 3.0 0.03
way ANOVA; EDSS: Kruskal-Wallis test.
rogressive; IQR inter-quartile range; EDSS Expanded Disability Status Scale.
Table 2 CCSVI classification by MS subtype









CCSVI diagnosis 153 (56.0%) 89/181 (49.2%) 58/80 (72.5%) 6/12 (50.0%) 0.002
Criterion 1 127 (46.5%) 76 (42.0%) 45 (56.2%) 6 (50.0%) 0.10
Criterion 2 98 (35.9%) 53 (29.3%) 40 (50.0%) 5 (41.7%) 0.005
Criterion 3 173 (63.4%) 115 (63.5%) 52 (65.0%) 6 (50.0%) 0.60
Criterion 4 28 (10.3%) 12 (6.6%) 15 (18.8%) 1 (8.3%) 0.012
Criterion 5 31 (11.4%) 12 (6.6%) 19 (23.8%) 0 (0%) < 0.001
Number of abnormal criteria 1.7 ± 1.1 1.5 ± 1.1 2.2 ± 1.1 1.5 ± 1.0 < 0.001
VHISS 2.9 ± 1.9 2.6 ± 1.8 3.7 ± 2.0 2.5 ± 1.6 < 0.001
MS multiple sclerosis; PP primary progressive, PR progressive relapsing; RR relapsing-remitting; SP secondary progressive; VHISS venous hemodynamic insufficiency
score.
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found. Similarly linear regression analyses (correcting for
sex and age) did not show association with CCSVI
(p= 0.49).
Disability status and CCSVI severity
The VHISS exhibited a trend with increasing age (Slope B
± SE: 0.007±0.0033, Wald χ2 = 4.54, p=0.033) in Poisson
regression with sex as a factor and age as a covariate. How-
ever there was no evidence for associations with EDSS.
VHISS was associated with the brainstem EDSS sub-
score (p= 0.002) and trends were found for the pyram-
idal (p= 0.026) and cerebellar (p= 0.051) sub-scores. The
probability of EDSS ≥ 4 was not associated with the se-
verity of CCSVI as assessed by VHISS (p= 0.056) in lo-
gistic regression correcting for age and sex.
Discussion and conclusion
The present study, a post hoc analysis of the original
CTEVD study, which aimed primarily to determine the
prevalence of CCSVI in MS patients, provides supplemen-
tary informative data to better understand the relation be-
tween MS and CCSVI criteria with a specific emphasis on
disease and disability status. The original CTEVD study
showed an increased prevalence of CCSVI in MS but sub-
stantially lower than the originally reported than the 100%
sensitivity and 100% specificity reported by Zamboni et al.
[3] as only 56.1% of MS patients and 38.1% of CIS patients
presented with abnormal venous ECD/TCD [9].
Bastianello et al. in a recent multicenter study evaluat-
ing 710 patients and using the Zamboni criteria [3]
showed a significant association between presence of
CCSVI (identified in 86%) and progressive disease [28].
The positive CCSVI patients had also higher disability
and a later disease onset as compared to the MS patients
without CCSVI. We can speculate that the presence of
CCSVI related to certain structural abnormalities as in-
competent valves or abnormal intra-luminal structuresas septums, flaps or webs can worsen with aging and/or
disease progression [29]. In fact, another study showed
that CCSVI was diagnosed in 50% of MS patients but
was seen also in 36% of the healthy controls [30]. No
correlation between presence of CCSVI and EDSS or
progressive disease was found, although this can be
related to the small number of progressive patients (15/
84) enrolled in this study [30]. Another smaller scale
study found no association between disease status and
CCSVI [16].
Although our large prevalence study showed higher fre-
quency of CSSVI in progressive MS compared to relapsing
MS, we did not obtain evidence for significant associations
with disability. The divergence of the prevalence and disabil-
ity data adds to the known difficulties of understanding and
measuring the effects of the two key pathological mechan-
isms in MS – inflammatory vs. neurodegeneration – by
introducing the presence of a VH dysfunction as a new vari-
able. Hemodynamic venous dysfunction may result in sec-
ondary tissue hypoperfusion that may be associated with a
continuous neurodegenerative process. Although VH dys-
function may be less related to the inflammatory aspects of
the disease, we speculate that abnormal VH may progres-
sively deteriorate in the context of the inflammatory milieu
and activation of the vascular endothelium that occurs in
MS [31]. Our previous findings in a OND group showing a
high prevalence of CCSVI in the majority of patients diag-
nosed with inflammatory diseases (i.e., anti-phospholipid
antibody syndrome, thyroiditis) [9]. CCSVI findings, if
present at all, may reflect: i) benign anatomical variants ii)
slower venous outflow due to global cerebral hypoperfusion
or iii) alterations to venous walls secondary to a chronic in-
flammation milieu.
In conclusion, our results indicate that features of
CCSVI have no relationship to disability in MS. Further
prospective studies including multimodal analysis (i.e.,
MRI/MRV, ECD/TCD) may help in providing more light
into the role of CCSVI or of VH dysfunction in MS.
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